Zura Bio (NASDAQ:ZURA) announced that it has launched a global Phase 2 study—TibuSHIELD—to evaluate tibulizumab in 180 adults with moderate to severe hidradenitis suppurativa (HS) across Canada, the U.S. and Europe.
According to Zura Bio, TibuSHIELD is the first study to evaluate the dual inhibition of a B-cell activating factor (BAFF) and interleukin-17A pathway in adults with HS. Topline results for the primary 16-week efficacy endpoint are expected in Q3 2026.
Kiran Nistala, MBBS, Ph.D., CMO, and head of development at Zura Bio, commented, “The initiation of TibuSHIELD marks a key milestone in our mission to advance potentially differentiated therapies for patients with severe inflammatory diseases. Tibulizumab’s dual mechanism of action, targeting both BAFF and IL-17A, offers a novel approach for the potential treatment of HS. We remain committed to advancing clinical development with investigators, clinical sites, and the HS community.”
